S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
AAPL   318.73 (+1.11%)
FB   222.14 (+0.17%)
MSFT   167.10 (+0.56%)
GOOGL   1,479.52 (+2.02%)
AMZN   1,864.72 (-0.70%)
CGC   24.89 (+2.43%)
NVDA   249.28 (+0.14%)
BABA   227.43 (+1.56%)
MU   57.66 (-0.03%)
GE   11.81 (-0.25%)
TSLA   510.50 (-0.58%)
AMD   50.93 (+2.33%)
T   38.38 (+0.92%)
ACB   2.13 (-0.93%)
F   9.16 (-0.11%)
NFLX   339.67 (+0.31%)
PRI   128.43 (+0.05%)
BAC   34.71 (-0.03%)
GILD   62.98 (-0.35%)
DIS   144.33 (-0.54%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
AAPL   318.73 (+1.11%)
FB   222.14 (+0.17%)
MSFT   167.10 (+0.56%)
GOOGL   1,479.52 (+2.02%)
AMZN   1,864.72 (-0.70%)
CGC   24.89 (+2.43%)
NVDA   249.28 (+0.14%)
BABA   227.43 (+1.56%)
MU   57.66 (-0.03%)
GE   11.81 (-0.25%)
TSLA   510.50 (-0.58%)
AMD   50.93 (+2.33%)
T   38.38 (+0.92%)
ACB   2.13 (-0.93%)
F   9.16 (-0.11%)
NFLX   339.67 (+0.31%)
PRI   128.43 (+0.05%)
BAC   34.71 (-0.03%)
GILD   62.98 (-0.35%)
DIS   144.33 (-0.54%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
AAPL   318.73 (+1.11%)
FB   222.14 (+0.17%)
MSFT   167.10 (+0.56%)
GOOGL   1,479.52 (+2.02%)
AMZN   1,864.72 (-0.70%)
CGC   24.89 (+2.43%)
NVDA   249.28 (+0.14%)
BABA   227.43 (+1.56%)
MU   57.66 (-0.03%)
GE   11.81 (-0.25%)
TSLA   510.50 (-0.58%)
AMD   50.93 (+2.33%)
T   38.38 (+0.92%)
ACB   2.13 (-0.93%)
F   9.16 (-0.11%)
NFLX   339.67 (+0.31%)
PRI   128.43 (+0.05%)
BAC   34.71 (-0.03%)
GILD   62.98 (-0.35%)
DIS   144.33 (-0.54%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
AAPL   318.73 (+1.11%)
FB   222.14 (+0.17%)
MSFT   167.10 (+0.56%)
GOOGL   1,479.52 (+2.02%)
AMZN   1,864.72 (-0.70%)
CGC   24.89 (+2.43%)
NVDA   249.28 (+0.14%)
BABA   227.43 (+1.56%)
MU   57.66 (-0.03%)
GE   11.81 (-0.25%)
TSLA   510.50 (-0.58%)
AMD   50.93 (+2.33%)
T   38.38 (+0.92%)
ACB   2.13 (-0.93%)
F   9.16 (-0.11%)
NFLX   339.67 (+0.31%)
PRI   128.43 (+0.05%)
BAC   34.71 (-0.03%)
GILD   62.98 (-0.35%)
DIS   144.33 (-0.54%)
Log in

NASDAQ:INSM - Insmed Stock Price, Forecast & News

$21.46
-1.23 (-5.42 %)
(As of 01/17/2020 04:00 PM ET)
Today's Range
$21.22
Now: $21.46
$23.02
50-Day Range
$22.60
MA: $23.82
$26.22
52-Week Range
$15.33
Now: $21.46
$33.13
Volume1.35 million shs
Average Volume1.03 million shs
Market Capitalization$1.92 billion
P/E RatioN/A
Dividend YieldN/A
Beta3.04
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:INSM
CUSIPN/A
Phone908-977-9900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$9.84 million
Book Value$2.70 per share

Profitability

Net Income$-324,280,000.00
Net Margins-291.19%

Miscellaneous

Employees373
Market Cap$1.92 billion
Next Earnings Date2/28/2020 (Estimated)
OptionableOptionable

Receive INSM News and Ratings via Email

Sign-up to receive the latest news and ratings for INSM and its competitors with MarketBeat's FREE daily newsletter.


The 5G Stock That Practically NOBODY Knows About... YET (Ad)


Its partners include AT&T, Verizon, Sprint and T-Mobile.

It owns more than 200 patents.

And analysts say it has "home-run potential."

Yet this 5G superstock trades for only $5 a share.

Insmed (NASDAQ:INSM) Frequently Asked Questions

What is Insmed's stock symbol?

Insmed trades on the NASDAQ under the ticker symbol "INSM."

How were Insmed's earnings last quarter?

Insmed Incorporated (NASDAQ:INSM) released its quarterly earnings data on Wednesday, October, 30th. The biopharmaceutical company reported ($0.68) EPS for the quarter, missing the Zacks' consensus estimate of ($0.67) by $0.01. The biopharmaceutical company had revenue of $38.89 million for the quarter, compared to the consensus estimate of $35.89 million. Insmed had a negative return on equity of 114.68% and a negative net margin of 291.19%. During the same period last year, the firm earned ($1.14) earnings per share. View Insmed's Earnings History.

When is Insmed's next earnings date?

Insmed is scheduled to release their next quarterly earnings announcement on Friday, February 28th 2020. View Earnings Estimates for Insmed.

What price target have analysts set for INSM?

7 Wall Street analysts have issued 12-month price objectives for Insmed's shares. Their forecasts range from $20.00 to $56.00. On average, they expect Insmed's stock price to reach $39.29 in the next twelve months. This suggests a possible upside of 83.1% from the stock's current price. View Analyst Price Targets for Insmed.

What is the consensus analysts' recommendation for Insmed?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insmed in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Insmed.

What are Wall Street analysts saying about Insmed stock?

Here are some recent quotes from research analysts about Insmed stock:
  • 1. According to Zacks Investment Research, "Insmed is a biopharmaceutical company engaged in the development and commercialization of ARIKAYCE, or liposomal amikacin for inhalation, for at least two identified orphan patient populations: patients with nontuberculous mycobacteria (NTM) lung infections and cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung infections. Insmed is also focused on the development of INS1009, the company's inhaled treprostinil prodrug for the treatment of pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs. " (1/2/2020)
  • 2. HC Wainwright analysts commented, "Our price target of $52/share is based on: (a) $51/share, as a 35x multiple of taxed and diluted FY28 GAAP EPS of $7.58 discounted back to and (b) an NPV of $52/share, (discount rate 12.0%, growth rate 2%), with both methods arriving at this target. Risks to our investment thesis and target price include: (1) failure of ALIS in the (2) failure of ALIS to achieve peak commercial revenue estimates in our model due to market size, penetration rates and/or pricing or other limiting factors." (4/9/2019)

Has Insmed been receiving favorable news coverage?

News coverage about INSM stock has trended somewhat positive recently, InfoTrie Sentiment reports. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Insmed earned a media sentiment score of 0.7 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Insmed.

Are investors shorting Insmed?

Insmed saw a drop in short interest in December. As of December 31st, there was short interest totalling 14,150,000 shares, a drop of 8.9% from the December 15th total of 15,540,000 shares. Based on an average daily volume of 945,200 shares, the short-interest ratio is presently 15.0 days. Currently, 16.7% of the company's shares are short sold. View Insmed's Current Options Chain.

Who are some of Insmed's key competitors?

What other stocks do shareholders of Insmed own?

Who are Insmed's key executives?

Insmed's management team includes the folowing people:
  • Mr. William H. Lewis J.D., Pres, CEO & Chairman (Age 50)
  • Mr. Paolo Tombesi, Chief Financial Officer (Age 55)
  • Ms. Christine A. Pellizzari J.D., Chief Legal Officer & Corp. Sec. (Age 51)
  • Mr. Roger Adsett, Chief Commercial Officer (Age 50)
  • Dr. Paul D. Streck, Advisor (Age 55)

How do I buy shares of Insmed?

Shares of INSM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Insmed's stock price today?

One share of INSM stock can currently be purchased for approximately $21.46.

How big of a company is Insmed?

Insmed has a market capitalization of $1.92 billion and generates $9.84 million in revenue each year. The biopharmaceutical company earns $-324,280,000.00 in net income (profit) each year or ($4.17) on an earnings per share basis. Insmed employs 373 workers across the globe.View Additional Information About Insmed.

What is Insmed's official website?

The official website for Insmed is http://www.insmed.com/.

How can I contact Insmed?

Insmed's mailing address is 10 Finderne Avenue Building 10, Bridgewater NJ, 08807. The biopharmaceutical company can be reached via phone at 908-977-9900 or via email at [email protected]


MarketBeat Community Rating for Insmed (NASDAQ INSM)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  429 (Vote Outperform)
Underperform Votes:  431 (Vote Underperform)
Total Votes:  860
MarketBeat's community ratings are surveys of what our community members think about Insmed and other stocks. Vote "Outperform" if you believe INSM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INSM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/17/2020 by MarketBeat.com Staff

Featured Article: Market Indexes

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel